Study shows safety of palbociclib for advanced breast cancer patients with unique gen
 

Women who receive palbociclib (Ibrance) to treat their advanced breast cancer and have a gene alteration that can lead to a condition known as benign ethnic neutropenia (BEN), can safely receive the drug without major concerns of developing infections associated with neutropenia, or low white blood cell counts, say Georgetown Lombardi Comprehensive Cancer Center researchers.

More...